T1	Outcomes 1381 1415	MEASURES Progression-free survival
T2	Outcomes 1498 1560	including overall survival, response rate, and safety/toxicity
T3	Outcomes 1979 1993	P < .001).
T4	Outcomes 1994 2017	Median overall survival
T5	Outcomes 2295 2321	selumetinib achieved tumor
